ICON.L

Iconic Labs Plc
Iconic Labs PLC - Result of AGM
13th February 2024, 14:08
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0017D
Iconic Labs PLC
13 February 2024
 

13 February 2024

Iconic Labs PLC

("Iconic" or the "Company")

Result of AGM

Iconic Labs PLC (LSE: ICON) is pleased to announce that at the Company's Annual General Meeting ('AGM') held earlier today, Resolutions 1 to 10 were all duly approved by shareholders by way of a poll.

At the meeting, inter alia, a resolution was passed which approved the sub-division and conversion of each existing ordinary share of £0.10 ("Existing Ordinary Shares") into one new ordinary share of £0.0001  (a "New Ordinary Share") and one deferred share of £0.0999 (a "Deferred Share") (each such Deferred Share having no voting or dividend rights and effectively being worthless) in order that the nominal value of a New Ordinary Share is less than the price of a share in the market.

As a result, the Company's issued share capital will consist of 11,161,483 ordinary shares of £0.0001 each with one voting right (and deferred shares of £0.0999 each with limited rights and which will not be admitted to trading). Admission in respect of such New Ordinary Shares will become effective and that dealings in those New Ordinary Shares will commence on 14 February 2024.

The above figure of 11,161,483 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The results of the poll were as follows: 

 

Resolutions

For

%

Against

%

Withheld

1

To receive and adopt the accounts for the financial year ended 30 June 2023.

3,374,840

99.19

27,718

0.81

4,837

2

To re-appoint RPG Chartered Accountants as Auditors.

3,369,888

99.17

28,070

0.83

9,437

3

To authorise the Directors to determine the remuneration of the Auditors.

3,369,670

99.03

32,888

0.97

 

4,837

4

To re-appoint Bradley Tyler Taylor as a Director.

3,205,262

94.20

197,226

5.80

4,907

5

To re-appoint Bela Lendvai-Lintner as a Director.

3,206,467

94.24

196,021

5.76

4,907

6

To re-appoint Victor Humberdot as a Director.

3,206,467

94.24

196,021

5.76

4,907

7

To authorise the Directors to allot shares up to a maximum aggregate nominal amount of £4,668,047.83.

3,193,245

94.06

201,631

5.94

12,519


Special Resolutions:






8

To empower the Directors to generally allot relevant equity securities.

3,193,597

94.07

201,279

5.93

12,519

9

Issued ordinary share capital be sub-divided and converted into one New Ordinary Share of £0.0001 and one Deferred Share of £0.0999.

3,192,372

93.91

207,104

6.10

7,919

10

To authorise the Directors to make market purchases of own shares.

3,371,803

99.19

27,673

0.81

7,919

 

 

 

- Ends -

 

For more information, please contact:

Iconic Labs

 

Brad Taylor, Chief Executive Officer

Tel: +44 (0) 7462 156238

Novum Securities Limited

David Coffman / Daniel Harris

Tel: +44 (0) 20 7399 9400

 

Yellow Jersey PR

Sarah Hollins

Annabelle Wills

Bessie Elliot

 

Tel: +44 (0) 20 3004 9512

iconic@yellowjerseypr.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGPUAAPUPCGPW]]>
TwitterFacebookLinkedIn